Antibacterial	antibacterial	O	O	O	O
medication	medication	O	O	O	O
use	use	O	O	O	O
during	during	O	O	O	O
pregnancy	pregnancy	O	O	O	O
and	and	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
birth	birth	O	DISEASE	OTHERS	I
defects	defects	O	DISEASE	OTHERS	I
:	:	O	O	O	O
National	national	O	O	O	O
Birth	birth	O	DISEASE	OTHERS	I
Defects	defects	O	DISEASE	OTHERS	I
Prevention	prevention	O	O	O	O
Study	study	O	O	O	O
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
estimate	estimate	O	O	O	O
the	the	O	O	O	O
association	association	O	O	O	O
between	between	O	O	O	O
antibacterial	antibacterial	O	O	O	O
medications	medications	O	O	O	O
and	and	O	O	O	O
selected	selected	O	O	O	O
birth	birth	O	DISEASE	OTHERS	I
defects	defects	O	DISEASE	OTHERS	I
.	.	O	O	O	O

DESIGN	design	O	O	O	O
,	,	O	O	O	O
SETTING	setting	O	O	O	O
,	,	O	O	O	O
AND	and	O	O	O	O
PARTICIPANTS	participants	O	O	O	O
:	:	O	O	O	O
Population-based	population-based	O	O	O	O
,	,	O	O	O	O
multisite	multisite	O	O	O	O
,	,	O	O	O	O
case-control	case-control	O	O	O	O
study	study	O	O	O	O
of	of	O	O	O	O
women	women	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
pregnancies	pregnancies	O	O	O	O
affected	affected	O	O	O	O
by	by	O	O	O	O
1	1	O	O	O	O
of	of	O	O	O	O
more	more	O	O	O	O
than	than	O	O	O	O
30	30	O	O	O	O
eligible	eligible	O	O	O	O
major	major	O	O	O	O
birth	birth	O	DISEASE	OTHERS	I
defects	defects	O	DISEASE	OTHERS	I
identified	identified	O	O	O	O
via	via	O	O	O	O
birth	birth	O	DISEASE	OTHERS	I
defect	defect	O	DISEASE	OTHERS	I
surveillance	surveillance	O	O	O	O
programs	programs	O	O	O	O
in	in	O	O	O	O
10	10	O	O	O	O
states	states	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
13	13	O	O	O	O
155	155	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
control	control	O	O	O	O
women	women	O	O	O	O
randomly	randomly	O	O	O	O
selected	selected	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
same	same	O	O	O	O
geographical	geographical	O	O	O	O
regions	regions	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
4941	4941	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

MAIN	main	O	O	O	O
EXPOSURE	exposure	O	O	O	O
:	:	O	O	O	O
Reported	reported	O	O	O	O
maternal	maternal	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
antibacterials	antibacterials	O	O	O	O
(	(	O	O	O	O
1	1	O	O	O	O
month	month	O	O	O	O
before	before	O	O	O	O
pregnancy	pregnancy	O	O	O	O
through	through	O	O	O	O
the	the	O	O	O	O
end	end	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
trimester	trimester	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

MAIN	main	O	O	O	O
OUTCOME	outcome	O	O	O	O
MEASURE	measure	O	O	O	O
:	:	O	O	O	O
Odds	odds	O	O	O	O
ratios	ratios	O	O	O	O
(	(	O	O	O	O
ORs	ors	O	O	O	O
)	)	O	O	O	O
measuring	measuring	O	O	O	O
the	the	O	O	O	O
association	association	O	O	O	O
between	between	O	O	O	O
antibacterial	antibacterial	O	O	O	O
use	use	O	O	O	O
and	and	O	O	O	O
selected	selected	O	O	O	O
birth	birth	O	DISEASE	OTHERS	I
defects	defects	O	DISEASE	OTHERS	I
adjusted	adjusted	O	O	O	O
for	for	O	O	O	O
potential	potential	O	O	O	O
confounders	confounders	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
reported	reported	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
antibacterials	antibacterials	O	O	O	O
increased	increased	O	O	O	O
during	during	O	O	O	O
pregnancy	pregnancy	O	O	O	O
,	,	O	O	O	O
peaking	peaking	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
third	third	O	O	O	O
month	month	O	O	O	O
.	.	O	O	O	O

Sulfonamides	sulfonamides	O	O	OTHERS	I
were	were	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
anencephaly	anencephaly	O	DISEASE	OTHERS	I
(	(	O	O	O	O
adjusted	adjusted	O	O	O	O
OR	or	O	O	O	O
[	[	O	O	O	O
AOR	aor	O	O	O	O
]	]	O	O	O	O
=	=	O	O	O	O
3.4	3.4	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
confidence	confidence	O	O	O	O
interval	interval	O	O	O	O
[	[	O	O	O	O
CI	ci	O	O	O	O
]	]	O	O	O	O
,	,	O	O	O	O
1.3	1.3	O	O	O	O
-	-	O	O	O	O
8.8	8.8	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
hypoplastic	hypoplastic	O	DISEASE	OTHERS	I
left	left	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
(	(	O	O	O	O
AOR	aor	O	O	O	O
=	=	O	O	O	O
3.2	3.2	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
1.3	1.3	O	O	O	O
-	-	O	O	O	O
7.6	7.6	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
coarctation	coarctation	O	O	OTHERS	I
of	of	O	O	OTHERS	I
the	the	O	O	OTHERS	I
aorta	aorta	O	O	OTHERS	I
(	(	O	O	O	O
AOR	aor	O	O	O	O
=	=	O	O	O	O
2.7	2.7	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
1.3	1.3	O	O	O	O
-	-	O	O	O	O
5.6	5.6	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
choanal	choanal	O	DISEASE	OTHERS	I
atresia	atresia	O	DISEASE	OTHERS	I
(	(	O	O	O	O
AOR	aor	O	O	O	O
=	=	O	O	O	O
8.0	8.0	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
2.7	2.7	O	O	O	O
-	-	O	O	O	O
23.5	23.5	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
transverse	transverse	O	O	OTHERS	I
limb	limb	O	O	OTHERS	I
deficiency	deficiency	O	O	OTHERS	I
(	(	O	O	O	O
AOR	aor	O	O	O	O
=	=	O	O	O	O
2.5	2.5	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
1.0	1.0	O	O	O	O
-	-	O	O	O	O
5.9	5.9	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
diaphragmatic	diaphragmatic	O	O	OTHERS	I
hernia	hernia	O	O	OTHERS	I
(	(	O	O	O	O
AOR	aor	O	O	O	O
=	=	O	O	O	O
2.4	2.4	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
1.1	1.1	O	O	O	O
-	-	O	O	O	O
5.4	5.4	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Nitrofurantoins	nitrofurantoins	O	O	OTHERS	I
were	were	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
anophthalmia	anophthalmia	O	O	OTHERS	I
or	or	O	O	O	O
microphthalmos	microphthalmos	O	O	OTHERS	I
(	(	O	O	O	O
AOR	aor	O	O	O	O
=	=	O	O	O	O
3.7	3.7	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
1.1	1.1	O	O	O	O
-	-	O	O	O	O
12.2	12.2	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
hypoplastic	hypoplastic	O	DISEASE	OTHERS	I
left	left	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
(	(	O	O	O	O
AOR	aor	O	O	O	O
=	=	O	O	O	O
4.2	4.2	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
1.9	1.9	O	O	O	O
-	-	O	O	O	O
9.1	9.1	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
atrial	atrial	O	O	OTHERS	I
septal	septal	O	O	OTHERS	I
defects	defects	O	O	OTHERS	I
(	(	O	O	O	O
AOR	aor	O	O	O	O
=	=	O	O	O	O
1.9	1.9	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
1.1	1.1	O	O	O	O
-	-	O	O	O	O
3.4	3.4	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
cleft	cleft	O	DISEASE	OTHERS	I
lip	lip	O	DISEASE	OTHERS	I
with	with	O	O	O	O
cleft	cleft	O	DISEASE	OTHERS	I
palate	palate	O	DISEASE	OTHERS	I
(	(	O	O	O	O
AOR	aor	O	O	O	O
=	=	O	O	O	O
2.1	2.1	O	O	O	O
;	;	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
1.2	1.2	O	O	O	O
-	-	O	O	O	O
3.9	3.9	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Other	other	O	O	O	O
antibacterial	antibacterial	O	O	O	O
agents	agents	O	O	O	O
that	that	O	O	O	O
showed	showed	O	O	O	O
associations	associations	O	O	O	O
included	included	O	O	O	O
erythromycins	erythromycins	O	O	OTHERS	I
(	(	O	O	O	O
2	2	O	O	O	O
defects	defects	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
penicillins	penicillins	O	O	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
defect	defect	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
cephalosporins	cephalosporins	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
defect	defect	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
quinolones	quinolones	O	O	OTHERS	I
(	(	O	O	O	O
1	1	O	O	O	O
defect	defect	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Reassuringly	reassuringly	O	O	O	O
,	,	O	O	O	O
penicillins	penicillins	O	O	OTHERS	I
,	,	O	O	O	O
erythromycins	erythromycins	O	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
cephalosporins	cephalosporins	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
although	although	O	O	O	O
used	used	O	O	O	O
commonly	commonly	O	O	O	O
by	by	O	O	O	O
pregnant	pregnant	O	O	O	O
women	women	O	O	O	O
,	,	O	O	O	O
were	were	O	O	O	O
not	not	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
many	many	O	O	O	O
birth	birth	O	DISEASE	OTHERS	I
defects	defects	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Sulfonamides	sulfonamides	O	O	OTHERS	I
and	and	O	O	O	O
nitrofurantoins	nitrofurantoins	O	O	OTHERS	I
were	were	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
several	several	O	O	O	O
birth	birth	O	DISEASE	OTHERS	I
defects	defects	O	DISEASE	OTHERS	I
,	,	O	O	O	O
indicating	indicating	O	O	O	O
a	a	O	O	O	O
need	need	O	O	O	O
for	for	O	O	O	O
additional	additional	O	O	O	O
scrutiny	scrutiny	O	O	O	O
.	.	O	O	O	O

